Stifel Nicolaus Issues Positive Forecast for Exact Sciences (NASDAQ:EXAS) Stock Price

Exact Sciences (NASDAQ:EXAS) had its price objective lifted by Stifel Nicolaus from $67.00 to $80.00 in a research note released on Tuesday morning, MarketBeat reports. Stifel Nicolaus currently has a buy rating on the medical research company’s stock.

A number of other brokerages have also recently weighed in on EXAS. Evercore ISI lifted their price target on shares of Exact Sciences from $64.00 to $68.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Zacks Research raised shares of Exact Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Barclays raised their price objective on shares of Exact Sciences from $65.00 to $77.00 and gave the company an “overweight” rating in a research note on Tuesday. UBS Group lowered their price objective on shares of Exact Sciences from $61.00 to $53.00 and set a “neutral” rating for the company in a research note on Thursday, August 7th. Finally, Wells Fargo & Company set a $68.00 price objective on shares of Exact Sciences in a research note on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $72.90.

Exact Sciences Price Performance

Shares of EXAS opened at $69.59 on Tuesday. Exact Sciences has a 1-year low of $38.81 and a 1-year high of $72.83. The stock has a market cap of $13.17 billion, a PE ratio of -12.82, a P/E/G ratio of 5.56 and a beta of 1.24. The firm has a 50-day simple moving average of $56.85 and a two-hundred day simple moving average of $53.02. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.89 and a quick ratio of 2.56.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.11. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The business had revenue of $850.74 million during the quarter, compared to analysts’ expectations of $810.42 million. During the same period last year, the business earned ($0.21) earnings per share. The business’s revenue for the quarter was up 20.0% on a year-over-year basis. Exact Sciences has set its FY 2025 guidance at EPS. As a group, analysts forecast that Exact Sciences will post -0.58 EPS for the current year.

Insider Transactions at Exact Sciences

In related news, Director James Edward Doyle sold 2,000 shares of Exact Sciences stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $60.00, for a total value of $120,000.00. Following the completion of the transaction, the director owned 57,962 shares in the company, valued at $3,477,720. The trade was a 3.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Westside Investment Management Inc. lifted its stake in Exact Sciences by 100.0% in the third quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock worth $31,000 after acquiring an additional 271 shares during the last quarter. True Wealth Design LLC lifted its stake in Exact Sciences by 951.8% in the second quarter. True Wealth Design LLC now owns 589 shares of the medical research company’s stock worth $31,000 after acquiring an additional 533 shares during the last quarter. Country Trust Bank purchased a new position in Exact Sciences in the second quarter worth approximately $32,000. Larson Financial Group LLC lifted its stake in Exact Sciences by 2,804.8% in the first quarter. Larson Financial Group LLC now owns 610 shares of the medical research company’s stock worth $26,000 after acquiring an additional 589 shares during the last quarter. Finally, Bessemer Group Inc. lifted its stake in Exact Sciences by 1,980.6% in the second quarter. Bessemer Group Inc. now owns 645 shares of the medical research company’s stock worth $34,000 after acquiring an additional 614 shares during the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.